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Irf4 is a positional and functional candidate gene for the
control of serum IgM levels in the mouse
J Coˆrte-Real, J Rodo, P Almeida, A Coutinho, J Demengeot and C Penha-Gonc¸alves
Instituto Gulbenkian de Cieˆncia, Oeiras, Portugal
Natural IgM are involved in numerous immunological functions but the genetic factors that control the homeostasis of its
secretion and upholding remain unknown. Prompted by the finding that C57BL/6 mice had significantly lower serum levels of
IgM when compared with BALB/c mice, we performed a genome-wide screen and found that the level of serum IgM was
controlled by a QTL on chromosome 13 reaching the highest level of association at marker D13Mit266 (LOD score¼ 3.54).
This locus was named IgMSC1 and covered a region encompassing the interferon-regulatory factor 4 gene (Irf4). The number
of splenic mature B cells in C57BL/6 did not differ from BALB/c mice but we found that low serum levels of IgM in C57BL/6 mice
correlated with lower frequency of IgM-secreting cells in the spleen and in the peritoneal cavity. These results suggested that
C57BL/6 mice have lower efficiency in late B-cell maturation, a process that is highly impaired in Irf4 knockout mice. In fact, we
also found reduced Irf4 gene expression in B cells of C57BL/6 mice. Thus, we propose Irf4 as a candidate for the IgMSC1
locus, which controls IgM homeostatic levels at the level of B-cell terminal differentiation.
Genes and Immunity (2008) 0, 000–000. doi:10.1038/gene.2008.73
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Introduction
Natural IgM play a significant role in the immunology of
health and disease. IgM antibodies are involved in
numerous immunological functions including protection
against infection,1–3 prevention of autoimmunity,4,5 B-cell
homeostasis6–8 and immunosurveillance against
tumors.9,10 IgM biological roles also include opsonization
of apoptotic cells, resulting in accelerated clearance by
phagocytic cells.11 Many of the circulating IgM corre-
spond to natural antibodies that exist prior to infection or
immunization.12–14 Natural IgM are polyreactive to
evolutionary conserved structures15 and bind efficiently
to previously un-encountered antigen.16 These antibodies
compensate their low-antigen affinity with relatively
high avidity and furthermore the effectiveness of the
antigen–antibody interaction is enhanced by the high
efficiency of IgM in engaging the complement path-
way.11,17
The preimmune Ig repertoire is thought to be
composed by mature B cells either recirculating through
follicles of secondary lymphoid organs (B2 cells), or
joining compartments in specific locations as the margin-
al zone in the spleen (MZ B-cells) and the pleural or
peritoneal cavities (B1 cells).12 B2 and marginal zone
B-cell development is initiated in the bone marrow and
completed in the periphery18,19 throughout life. B cells
exported from the bone marrow maturate in the spleen20
into subsets that differ in their surface phenotype,
anatomic localization and immunologic function21–23
and that ultimately are able to differentiate into anti-
body-producing plasma cells, upon antigenic stimula-
tion.18 Most frequently primary antigen contact of
mature naive B cells leads to IgM production detectable
in the serum.
On the other hand, studies on germ-free and axenic
mice suggest that in the absence of pathogens such
stimulation is conveyed by the action of self-antigens,
leading to production of natural antibodies.24,25 The B1
cell population, is derived almost exclusively from foetal
liver,26 is established early in ontogeny and is predomi-
nantly maintained by self-replenishment.27 These cells
locate preferentially in the pleural and peritoneal
cavities26 and spontaneously secrete natural Ig28 partici-
pating in relatively few antigen-stimulated antibody
responses.26
The capacity for Ig secretion is acquired in the process
of B-cell terminal differentiation,29 at the plasma cell
stage and requires the expression of the transcription
factor Irf4,30 a member of the interferon-regulatory factor
(IRF) family.31 Irf4 expression is induced by antigen
receptor or mitogen stimulation32 and is restricted to cells
of the immune system,33,34 playing a critical role in both
early35 and late B-cell differentiation.30 Interestingly, Irf4
upregulation results in spontaneous differentiation of B
cells into plasma cells and production of IgM in the
absence of external stimuli.36
Several familiarity and genetic studies have indicated
that heritable components control the serum levels of
IgE, IgA and IgG37–39 and identified a number of loci
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influencing total serum levels of these antibodies in
humans.40–42 There is also convincing evidence for
parent–offspring effects and genetic heritability in hu-
man serum IgM levels37–39 as well as evidence for genetic
control of natural IgM titers in mammals,43 birds44 and
fish.45 However, no linkage evidence for quantitative trait
loci influencing serum IgM has been reported and the
genetics of the homeostatic regulation of serum IgM
remains largely unknown. Here, we characterized a total
IgM serum phenotype in mouse inbred strains and
performed a genome-wide screen that identified a region
on mouse chromosome 13 that contained a locus (loci)
controlling IgM serum levels. Searching for the cellular
and genetic basis of serum IgM phenotype we correlated
the level of serum IgM with the frequency of IgM-
producing cells and the expression of the Irf4 gene.
Results
Serum IgM phenotype
To investigate the genetic control of serum IgM we
analyzed the IgM concentration in the serum of C57BL/6
and BALB/c inbred strains. We found that the serum
IgM level was lower in C57BL/6 than in BALB/c mice,
albeit the phenotype showed reduced penetrance
(Figure 1). The F1 [C57BL/6 X BALB/c] generation
showed an intermediate phenotype and an F2 [C57BL/6
X BALB/c] progeny of 136 mice showed a phenotype
spectrum, from low to high values, indicating that alleles
controlling the phenotype were segregating in the cross
(Figure 1). The serum IgM trait, measured as the
logarithm of IgM concentration, was normally distrib-
uted in the F2 [C57BL/6 X BALB/c] progeny required for
quantitative trait locus (QTL) analysis (data not shown).
Genetic mapping of serum IgM phenotype
We performed a QTL analysis for this trait scanning the
genome with 100 microsatellite markers in the 136 F2
progeny. We found that a region in proximal mouse
chromosome 13 was linked to the serum IgM trait, with a
95% confidence interval between the markers D13MIT57
and D13MIT179, where the highest associated marker
D13Mit266 reached an LOD score of 3.54 corresponding
to an empirically estimated genome-wide P-value of 0.04.
The chromosome 13 locus was named IgMSC1 (IgM-
secreting cells locus 1; Figure 2a) and covered a region
encompassing the Irf4 gene. Although no other chromo-
somal region reached the level of genomic significance,
suggestive LOD scores were detected in chromosome 7
at marker D7MIT318 (LOD 2.05) and in chromosome 9 at
marker D9MIT53 (LOD 2.02) that could represent
Gene : NPGGENEgene200873
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Figure 1 Serum IgM levels in naive mice. IgM serum concentration
was measured in eight C57BL/6 (black circles), 10 BALB/c (white
circles), seven F1 [C57BL/6 X BALB/c] (black triangles) and 136 F2
[C57BL/6 X BALB/c] (white diamonds) mice by Indirect ELISA.
Average concentrations are shown as horizontal bars.
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Figure 2 (a) Mapping the IgMSC1 locus. LOD score curve for
mouse chromosome 13 represents the likelihood for linkage of the
serum IgM trait with the represented markers. Regions of
significant linkage show LOD score above 3.0. The x axis ticks
represent the relative position of microsatellite markers along this
chromosome, from left to right: D13Mit236, 4 cM; D13Mit57, 9 cM;
D13Mit115, 11 cM; D13Mit266, 16 cM; D13Mit88, 21 cM; D13Mit179,
30 cM; D13Mit159, 47 cM; D13Mit147, 49 cM; D13Mit262, 68 cM; and
D13Mit78, 75 cM. (b) IgM serum trait control by the IgMSC1 locus.
The F2 (C57BL/6 X BALB/c) mice were classified according to their
genotype at D13Mit266 and the mean trait value and the s.e. are
represented for each group.
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additional loci controlling the serum IgM phenotype,
albeit with a smaller genetic effect as compared with
IgMSC1. To evaluate the IgMSC1 genetic effect in the
serum IgM phenotype F2 mice were classified according
to their genotype at the highest linked marker in the
IgMSC1 locus (D13Mit266). This analysis shows that the
IgMSC1 locus has an additive mode of action (Figure 2b)
and controls a significant fraction of the phenotypic
variance (15.5%).
IgM-secreting cells and serum IgM
With the aim of determining the cellular basis of the IgM
serum trait we started by counting the total number of B
cells, sIgMþ B cells and IgM-secreting cells in the spleen
of C57BL/6 and BALB/c adult mice. We found no
significant differences in the total number of B cells or in
the total number of mature sIgMþ B cells (data not
shown), suggesting that regulation of B-cell spleen
cellularity and B-cell maturation in the spleen is similar
in these strains. However, we also found that C57BL/6
have significantly lower number of IgM-secreting cells in
the spleen, offering an explanation for the observed
lower serum IgM phenotype (Figure 3). Moreover, we
purified B-cell populations to show that the number of
IgM-secreting cells within splenic B cells was lower in
C57BL/6, suggesting that these mice have less efficient
plasma cell differentiation as compared with BALB/c
mice (Figure 4a). These findings suggested that the
cellular basis for the serum IgM trait resides in final steps
of the peripheral B-cell maturation and terminal differ-
entiation in the spleen.
It has been described that the B-cell population (B1)
localizing in the pleural and peritoneal cavities is an
important source of natural IgM in the mouse.46 To assess
the contribution of peritoneal B cells to the observed
phenotype we decided to characterize the population of
B cells and IgM-secreting cells in the peritoneal cavity of
C57BL/6 and BALB/c mice. We found that C57BL/6
mice have a decreased number of IgM-secreting cells in
the peritoneal cavity when compared with the BALB/c
strain (Figure 4b). Thus, the number of IgM-secreting
B cells in the peritoneal cavity may also contribute to the
cellular basis of the serum IgM trait in these mouse
strains. These data indicate that the reduced number of
IgM-secreting cells in the C57BL/6 mice is not specific of
the spleen environment and appears to be an intrinsic
genetic property of the B-cell compartment.
Irf4 gene expression
The Irf4 gene is a key player in several stages of B-cell
development, namely in controlling plasma cell differ-
entiation30,35 and co-localizes with IgMSC1 on chromo-
some 13. In principle, several genes in the region flanked
by D13MIT115 and D13MIT88 that encompass the
highest linked marker in the IgMSC1 locus could
mediate the observed IgM serum phenotype. Never-
theless, the Irf4 gene is the most plausible functional
candidate in this interval as it was earlier related to
antibody secretion.30,35 To ascertain whether the Irf4 gene
could be involved in controlling the serum IgM trait, we
quantified Irf4 RNA by real-time PCR in purified B cells
from the spleen and the peritoneal cavity. We found that
Irf4 expression was significantly reduced in splenic B
cells and in peritoneal cavity B cells from the C57BL/6
(Figure 5). These data strongly suggest that Irf4 is a
candidate gene to IgMSC1 and contributes to the serum
IgM phenotype by controlling the number of IgM-
secreting cells.
Discussion
In this work we used a mouse genome screen approach
to search for genetic factors that control the IgM levels in
the serum. We identified a major locus on mouse
chromosome 13 controlling the IgM serum concentration
that we called IgM-secreting cells locus 1 (IgMSC1). Our
results support a correlation of this phenotype with the
number of IgM-producing cells in the spleen and in the
peritoneal cavity, leading us to hypothesize that the
IgMSC1 controls IgM serum concentration by regulating
the differentiation and/or maintenance of plasma cells
both in the spleen and in the peritoneal cavity. It has been
described that the serum anti-RBC IgM concentration is
linked to the 40–49.5 cM region on chromosome 1347 and
we show that gene(s) controlling natural IgM secretion
are also localized in this chromosome. However, the anti-
RBC locus (40–49.5 cM) and the IgMSC1 locus (9–30 cM)
are somewhat apart on chromosome 13 raising the
possibility that they would not correspond to the same
genetic factor. We noted that the IgG serum concentration
in C57BL/6 mice was significantly higher as compared
with BALB/c and that IgMSC1 was not controlling levels
of serum IgG in the genetic cross we analyzed (data not
shown). This indicates that the genetic mechanisms that
control IgM and IgG serum steady state levels have
distinct and independent components.
The IgMSC1 locus is tightly linked to the Irf4 gene
region on mouse chromosome 13 and we showed that
the relative expression of this transcription factor is
reduced in C57BL/6 B cells isolated from the spleen and
from the peritoneal cavity. Thus, we propose the
interferon-regulatory factor 4 as a candidate gene to
mediate the IgMSC1 phenotypic effect.
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Figure 3 Number of IgM-secreting cells in the spleen correlates
with serum IgM concentration. The values represent results that
were obtained by ELISA-Spot-Assay and indirect ELISA in
individual C57BL/6 and BALB/c mice.
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A series of recent studies have demonstrated critical
functions for IRF-4 at several stages of B-cell develop-
ment, where it seems to preferentially limit clonal
expansion and promote differentiation processes.32,48
Irf4 is a member of the interferon-regulatory factor
family of transcription factors characterized by a specific
DNA-binding domain and has the ability to either
activate or repress the transcription of interferon-indu-
cible genes.18,31 Expression of Irf4 is restricted to cells of
the immune system, including lymphocytes, dendritic
cells and macrophages, in which it has been linked to a
variety of functions, such as proliferation, apoptosis and
differentiation.33,34,49 Irf4 knockout mice have normal
early B-cell development but profound reduction in
serum immunoglobulin concentrations and show incap-
ability to mount antibody responses because of a late-
stage blockage in peripheral B-cell maturation that leads
to the absence of plasma cells, plasmablasts and class-
switched B cells.30,35 Recently, the Irf4 gene has been
demonstrated to have a biphasic expression pattern: it is
expressed in immature B cells in the bone marrow,48
absent from proliferating germinal center centroblasts
and then re-expressed in a subpopulation of centrocytes
in the germinal center and in plasma cells.50 Extending
these studies, the evidences provided here introduce the
notion that natural genetic variation at the Irf4 gene
impacts in its expression levels, being a major factor in
the quantitative control of terminal B-cell differentiation
and, consequently of natural IgM serum concentration.
It is plausible that a differential effect of Irf4 alleles
could explain, at least in part, the observed differences in
frequency of IgM-secreting cells and IgM serum con-
centration when we compared the C57BL/6 and BALB/c
mouse strains. It is reported that the coding region of the
Irf4 gene in C57Bl/6 and BALB/c mice shows no
sequence differences except for a synonymous point
mutation in the exon 6 (NCBI entries with accession
numbers AAA75309.1 and AAA75283.1). On the other
hand, regulatory elements have been described in the
Gene : NPGGENEgene200873
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Figure 4 Decreased number of IgM secreting cell counting in purified splenic B cells and purified peritoneal cavity B cells in C57BL/6 mice.
(a) Number of IgM-secreting cells in splenocyte B cells pooled from groups of eight mice. The results represent the mean and s.d. of triplicate
samples assayed simultaneously. (b) Number of IgM-secreting cells in peritoneal cavity B cells pooled from groups of five mice and
representing the mean and s.d. of two separate experiments assayed in triplicates.
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Figure 5 Irf4 gene expression is decreased in purified B cells from
the splenic and peritoneal cavity of C57BL/6 mice. RNA of the Irf4
gene was quantified in purified B cells from spleens of five C57BL/6
(black bars) and five BALB/c (white bars) adult mice or in purified
B cells from pooled peritoneal cavity lavages of five C57BL/6 (black
column) or five BALB/c (white column) adult mice. The results
represent the mean and s.d. of the average of samples assayed
simultaneously.
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human Irf4 gene encompassing the 5 kb upstream the Irf4
coding region.51 However, we have sequenced 4763 bp
upstream the translational starting site of the Irf4 gene
and did not find sequence differences between C57Bl/6
and BALB/c mice. Thus, it is possible that the allelic
variation controlling the observed differences in RNA
expression lies in yet unidentified Irf4 gene regulatory
regions. In fact, the functional conformation of the Irf4
promoter region suggests that its expression is strictly
regulated in the chromatin context.51 Detailed functional
studies of the control region of the mouse Irf4 gene
would be needed to enable a systematic analysis of the
differential expression of the C57Bl/6 and BALB/c Irf4
alleles.
This work highlighted a region on mouse chromosome
13 that contains genetic factor(s) involved in the circuitry
of the serum immunoglobulin homeostasis and led us to
hypothesize that allelic variation in the Irf4 gene may
control the homeostasis of serum IgM in the mouse at the
level of the generation of antibody-producing cells.
These findings may motivate human studies on the
genetic control of IgM and natural antibody levels in
normal individuals and in the context of Ig deficiencies
and inflammatory autoimmune diseases, particularly
focused on genes mapping in the region ortholog to
IgMSC1, including the Irf4 gene.
Materials and methods
Mice
The mouse strains used in this study included the
C57BL/6 and BALB/c as well as mice from the genetic
crosses F1 (C57BL/6 X BALB/c) and F2 (C57BL/6 X
BALB/c). All mice were females between 6 and 8 months
of age, bred and maintained in conventional housing
facilities at the Instituto Gulbenkian de Cieˆncia. F1
(C57BL/6 X BALB/c) mice were used to generate an F2
(C57BL/6 X BALB/c) progeny of 136 animals.
Genotyping
Genomic DNA was extracted from mouse tails with
standard digestion/precipitation methods. The F2 gen-
eration was genotyped using 100 microsatellite DNA
markers, polymorphic for the parental strains. Markers
were chosen according to their chromosomal position as
given by the Broad Institute for genome research (USA),
to cover uniformly the whole mouse genome at an
average density of 20 cM. The genotypes for each locus
were determined by DNA marker amplification using
conventional PCR techniques. Amplification products
were analyzed in 4% agarose gels (Cambrex BioScience,
USA) with ethidium bromide (Sigma-Aldrich, USA) and
the allele size was determined using the Eagle Eye II
video system (Stratagene, USA). Each individual of the
F2 progeny was typed for each marker as homozygous
for one or the other parental strain or as heterozygous
when presenting both the parental strain alleles.
IgM serum concentration
Standard indirect ELISA was used to quantify total IgM
concentrations in mouse sera. Briefly, flat-bottomed
96-well ELISA plates were coated overnight at 4 1C, with
goat anti-mouse-IgM-UNLB human adsorbed antibody
(Southern Biotech., Birmingham, AL, USA) diluted in
coating buffer (0.05 M Na2CO3). The plates were washed
with PBS, blocked with PBS-gelatin 1% and incubated at
37 1C for 60 min. After washing, eight serial dilutions of
sera to be tested (starting at 1:90 and using 1:3 dilution
steps) were incubated for 60 min at 37 1C and washed.
Bound seric IgM was detected by the peroxidase-
conjugated goat anti-mouse IgM-HRP human adsorbed
antibody (Southern Biotech.) diluted in PBS-Gelatin
1%-Tween 0.075% (1:4000), revealed with the substrate
o-phenylenediamine (Calbiochem, USA) and H2O2 and
the OD read at 490 nm. The concentrations of IgM
antibody in the samples were calculated against standard
curves obtained with purified monoclonal IgM
(mouse-IgM UNLB, clone 11E10, Southern Biotech.)
tested in the same microtiter plate.
Genetic analysis
Quantitative trait locus analysis was performed by using
the normal model in the R/QTL software.52 This
program calculates logarithm of odds (LOD scores) over
intervals between linked markers, generating likelihood
plots of genetic association with the phenotype across the
genotyped chromosomal regions. The genome-wide
statistical significance of the results was empirically
determined by performing permutation tests53 and the
QTL confidence interval was calculated using the
Bayesian method of R/QTL as formulated by Karl
Bromam in http://www.rqtl.org/manual/html/baye-
sint.html.
IgM-secreting cells
The number of IgM-secreting cells was determined by
ELISA-Spot-Assay (ESA). The plates were coated over-
night at 4 1C with goat anti-mouse IgM-human adsorbed
(Southern Biotech.), diluted in coating buffer (0.05 M
Na2CO3) and the plates saturated with PBS containing
1% gelatin. Serial three-fold dilutions of total splenocytes
(starting with 106 cells), spleen purified B-cells (starting
with 3 106 cells) or sorted peritoneal cavity B cells
(starting with 7.5 103 cells) were performed in RPMI-
1640 medium supplemented with 10% heat inactivated
fetal calf serum (FCS), 2 mM L-glutamine, 10 mM HEPES
(pH 7.4), 50 mM 2-mercaptoethanol, 100 U penicillin and
100 mg ml1 streptomycin (all from Life Technologies,
NY, USA). Cell dilutions were added and the plates were
sealed and incubated overnight at 37 1C in a humidified
5% CO2 atmosphere. Non-adherent cells were thereafter
removed by flicking the plate followed by lysis with 0.1%
Tween 20 in water. After extensive washing with PBS
containing 0.05% Tween 20 the plates were incubated
with goat anti-mouse IgM-AP-conjugated antibody
(Southern Biotech.), washed again and revealed with
BCIP-AMP substrate (2.3 mM of 5-bromo-4-chloro-3-
indolyl phosphate diluted in 2-amino-2-methyl-1-propa-
nol buffer, Sigma, St Louis, MO, USA). After incubation
overnight at 4 1C and washing three times with distilled
water, the traces of IgM-secreting cells were revealed as
blue spots and counted.
B-cell purification
Splenocyte suspensions were prepared by straining of
the spleens through a nylon mesh and peritoneal cavity
cell suspensions were obtained from peritoneal lavage
with 7 ml of PBS supplemented with 2% FCS. Purified B
cells, with an average purity of 98%, were obtained from
Gene : NPGGENEgene200873
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splenocyte and peritoneal cavity cell suspensions
through high speed cell sorting (MoFlo, Cytomation
Inc., USA), after labeling with FITC-anti-mouse CD19
(clone 1D3, BD Biosciences, CA, USA).
RNA isolation and real-time PCR
Total RNA from sorted splenic and peritoneal B cells was
obtained using an RNeasy Mini Kit (Qiagen), following
the manufacturer’s protocol for animal cells. RNA was
converted to cDNA (Transcriptor First Strand cDNA
Synthesis Kit, Roche) using random hexamer primers.
Irf4 (Mm0051634-m1) expression was quantified using
TaqMan Gene Expression Assays from ABI with TaqMan
Universal PCR master mix. The gene expression quanti-
fication reactions were performed in an ABI Prism
7900HT system. Relative quantification of Irf4
(Mm0051634-m1) in each real-time PCR was obtained
after normalization for GAPDH expression measured in
the same PCR and used the 2DDCT analysis method.54
Statistical analysis
Statistically significant differences in serum IgM con-
centration, B-cell number, IgM-secreting cell number and
Irf4-relative expression were estimated by Student’s
t-test. Differences with Po0.05 were considered
significant.
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